SCHEMBL6322197

SCHEMBL6322197

Cc1ccsc1-c1noc(N)c1C(=O)NCC1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
BCL2 P10415 1/20 0.40
BCL2L1 Q07817 1/20 0.40
MCL1 Q07820 1/20 0.40
BCL2A1 Q16548 1/20 0.40
CNR1 P21554 2/20 0.39
KIT P10721 1/20 0.39
POLB P06746 1/20 0.39
MMP13 P45452 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.38
CA2 P00918 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318769 0.95 NPSR1 (0.42) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL6320752 0.88 HIF1A (0.52) ALDH1A1KDM4ENPC1HPGDHTT
SCHEMBL6315616 0.84 KMT2A (0.47) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL6324296 0.84 KMT2A (0.47) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL6315866 0.83 KMT2A (0.46) ALDH1A1KDM4ENPC1HPGDRAB9A
SCHEMBL6316333 0.81 KDM4E (0.43) ALDH1A1KDM4ENPC1HPGDHTT
SCHEMBL6317149 0.81 KMT2A (0.43) ALDH1A1KDM4ENPC1HPGDRAB9A
SCHEMBL6318857 0.80 NPSR1 (0.42) ALDH1A1KDM4ENPC1HPGDHTT
SCHEMBL6322906 0.80 GAA (0.42) ALDH1A1KDM4ENPC1HPGDHTT
SCHEMBL6317732 0.80 TAS1R3 (0.47) KDM4EHTTPOLBTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALDH1A1 4444/4885KDM4E 1382/4885NPC1 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.